In addition to neuraminidase inhibitors and other drugs that directly target viral replication, a
number of adjunctive and immunomodulatory therapies are currently under evaluation for …

The value of adjunctive immunomodulatory therapies in treating severe influenza and other
respiratory viral infections remains uncertain. Although often used, systemic corticosteroids …

A severe inflammatory immune response with hypercytokinemia occurs in patients
hospitalized with severe influenza, such as avian influenza A (H5N1), A (H7N9), and …

Influenza A virus is a significant cause of morbidity and mortality worldwide. Severe
influenza is recognized as a clinical syndrome, characterized by hyperinduction of …

Introduction: Over the last century several influenza outbreaks have traversed the globe,
most recently the influenza A (H1N1) 2009 pandemic. On each occasion, a highly …

Background A range of immunomodulatory therapies have been proposed as adjuncts to
conventional antivirals to suppress harmful inflammation during severe influenza infection …

Clinicians, who may have only seen the media headlines following discussion of reviews
which deal with randomized controlled trials of neuraminidase inhibitor drug use in mild …

Highlights•Resistance and timely treatment are challenges for approved influenza
antivirals.•Structure insights on RNP functional domains aid development of novel …

Influenza is a major acute respiratory infection that causes mortality and morbidity
worldwide. Two classes of conventional antivirals, M2 ion channel blockers and …

Objective: To determine the impact of adjuvant corticosteroids administered to patients
hospitalized with influenza A (H7N9) viral pneumonia. Design: The effects of adjuvant …